• News
  • SAN DIEGO
  • Medical

OncoSec Medical announces $7.2M public offering

OncoSec Medical Inc. entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

The company is developing an advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers.

The offering is expected to close on Dec. 17, subject to customary closing conditions.

OncoSec has agreed to sell to institutional investors an aggregate of 28.8 million shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14.4 million shares of common stock at an exercise price of $0.26 per share for a term of four years.

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

Dawson James Securities Inc. acted as the exclusive placement agent for the transaction. Burrill LLC and Noble Financial Capital Markets acted as financial advisers to OncoSec in connection with the transaction.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

OncoSec Medical Inc.

Company Website

4690 Executive Dr. Ste., 250
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ONCS
4.31
  0.25  
+ 6.16%
128,643,000
13.19
3.37

OncoSec Medical Inc. Executive(s):

Punit Dhillon

  • Chief Executive Officer, President

Veronica Vallejo

  • Chief Financial Officer
Subscribe Today!